222 related articles for article (PubMed ID: 30950375)
41. Journal of Translational Medicine advances in Translational Genomics and Genetics Era.
Liu W
J Transl Med; 2019 Apr; 17(1):134. PubMed ID: 31023327
[TBL] [Abstract][Full Text] [Related]
42. [From panel diagnostics to comprehensive genomic analysis : Infobesity or empowerment?].
Leichsenring J; Kazdal D; Ploeger C; Allgäuer M; Endris V; Volckmar AL; Neumann O; Kirchner M; Penzel R; Rempel E; Budczies J; Schirmacher P; Fröhling S; Stenzinger A
Pathologe; 2019 May; 40(3):235-242. PubMed ID: 31089797
[TBL] [Abstract][Full Text] [Related]
43. Next-generation sequencing and empowering personalised cancer medicine.
McDermott U
Drug Discov Today; 2015 Dec; 20(12):1470-5. PubMed ID: 26494142
[TBL] [Abstract][Full Text] [Related]
44. Next generation sequencing for clinical diagnostics and personalised medicine: implications for the next generation cardiologist.
Ware JS; Roberts AM; Cook SA
Heart; 2012 Feb; 98(4):276-81. PubMed ID: 22128206
[TBL] [Abstract][Full Text] [Related]
45. OpenGeneMed: a portable, flexible and customizable informatics hub for the coordination of next-generation sequencing studies in support of precision medicine trials.
Palmisano A; Zhao Y; Li MC; Polley EC; Simon RM
Brief Bioinform; 2017 Sep; 18(5):723-734. PubMed ID: 27422621
[TBL] [Abstract][Full Text] [Related]
46. The SickKids Genome Clinic: developing and evaluating a pediatric model for individualized genomic medicine.
Bowdin SC; Hayeems RZ; Monfared N; Cohn RD; Meyn MS
Clin Genet; 2016 Jan; 89(1):10-9. PubMed ID: 25813238
[TBL] [Abstract][Full Text] [Related]
47. Implementing Genome-Driven Oncology.
Hyman DM; Taylor BS; Baselga J
Cell; 2017 Feb; 168(4):584-599. PubMed ID: 28187282
[TBL] [Abstract][Full Text] [Related]
48. Roadmap for Establishing Large-Scale Genomic Medicine Initiatives in Low- and Middle-Income Countries.
Patrinos GP; Pasparakis E; Koiliari E; Pereira AC; Hünemeier T; Pereira LV; Mitropoulou C
Am J Hum Genet; 2020 Oct; 107(4):589-595. PubMed ID: 33007198
[TBL] [Abstract][Full Text] [Related]
49. Sequencing-based diagnostics for pediatric genetic diseases: progress and potential.
Abou Tayoun AN; Krock B; Spinner NB
Expert Rev Mol Diagn; 2016 Sep; 16(9):987-99. PubMed ID: 27388938
[TBL] [Abstract][Full Text] [Related]
50. Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations.
Allegretti M; Fabi A; Buglioni S; Martayan A; Conti L; Pescarmona E; Ciliberto G; Giacomini P
J Exp Clin Cancer Res; 2018 Mar; 37(1):47. PubMed ID: 29506529
[TBL] [Abstract][Full Text] [Related]
51. Predictive and Precision Medicine with Genomic Data.
Baudhuin LM; Biesecker LG; Burke W; Green ED; Green RC
Clin Chem; 2020 Jan; 66(1):33-41. PubMed ID: 31843866
[No Abstract] [Full Text] [Related]
52. Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life.
Morganti S; Tarantino P; Ferraro E; D'Amico P; Viale G; Trapani D; Duso BA; Curigliano G
Crit Rev Oncol Hematol; 2019 Jan; 133():171-182. PubMed ID: 30661654
[TBL] [Abstract][Full Text] [Related]
53. Toward multiomics-based next-generation diagnostics for precision medicine.
Wang Q; Peng WX; Wang L; Ye L
Per Med; 2019 Mar; 16(2):157-170. PubMed ID: 30816060
[TBL] [Abstract][Full Text] [Related]
54. Precision medicine in Thailand.
Shotelersuk V; Tongsima S; Pithukpakorn M; Eu-Ahsunthornwattana J; Mahasirimongkol S
Am J Med Genet C Semin Med Genet; 2019 Jun; 181(2):245-253. PubMed ID: 30888117
[TBL] [Abstract][Full Text] [Related]
55. Omics-Based Strategies in Precision Medicine: Toward a Paradigm Shift in Inborn Errors of Metabolism Investigations.
Tebani A; Afonso C; Marret S; Bekri S
Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27649151
[TBL] [Abstract][Full Text] [Related]
56. Data resources for the identification and interpretation of actionable mutations by clinicians.
Prawira A; Pugh TJ; Stockley TL; Siu LL
Ann Oncol; 2017 May; 28(5):946-957. PubMed ID: 28327901
[TBL] [Abstract][Full Text] [Related]
57. Incidentalome from Genomic Sequencing: A Barrier to Personalized Medicine?
Jamuar SS; Kuan JL; Brett M; Tiang Z; Tan WL; Lim JY; Liew WK; Javed A; Liew WK; Law HY; Tan ES; Lai A; Ng I; Teo YY; Venkatesh B; Reversade B; Tan EC; Foo R
EBioMedicine; 2016 Mar; 5():211-6. PubMed ID: 27077130
[TBL] [Abstract][Full Text] [Related]
58. From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards.
Perera-Bel J; Hutter B; Heining C; Bleckmann A; Fröhlich M; Fröhling S; Glimm H; Brors B; Beißbarth T
Genome Med; 2018 Mar; 10(1):18. PubMed ID: 29544535
[TBL] [Abstract][Full Text] [Related]
59. Advances in whole genome sequencing technology.
Zhao J; Grant SF
Curr Pharm Biotechnol; 2011 Feb; 12(2):293-305. PubMed ID: 21050163
[TBL] [Abstract][Full Text] [Related]
60. Translating personalized genomic medicine into clinical practice: evidence, values, and health policy.
Bombard Y
Genome; 2015 Dec; 58(12):491-7. PubMed ID: 26577841
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
